Class / Patent application number | Description | Number of patent applications / Date published |
514200100 | Protease inhibitor affecting or utilizing | 55 |
20150080289 | PEPTIDES AND USES THEREOF - Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides. | 03-19-2015 |
20110183919 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 07-28-2011 |
20110195912 | Oligomer-Protease Inhibitor Conjugates - Provided are small molecule drugs that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water soluble oligomer. | 08-11-2011 |
20120094928 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-19-2012 |
20120094929 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-19-2012 |
20120094930 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-19-2012 |
20120202751 | METHODS OF MONITORING ENDOPLASMIC RETICULUM (ER) STRESS RESPONSE - Transgenic mammals, cells derived from the animals, and methods of using these to monitor the endoplasmic reticulum (ER) stress response are provided. In some embodiments, the methods allow for monitoring the ER stress response in real time. Some of the methods allow non-invasive in vivo visualization of ER stress response. Also provided are methods of screening molecules and/or treatment conditions for the ability to modulate the ER stress response, methods of treating diseases characterized by ER stress response activity, and methods of detecting the toxicity or therapeutic ratio of molecules that modulate the ER stress response. | 08-09-2012 |
20120270803 | Mitotic Kinesin Inhibitors and Methods of Use Thereof - This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. | 10-25-2012 |
20120322744 | POLY-PEGYLATED PROTEASE INHIBITORS - Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods. | 12-20-2012 |
20120322745 | OPTIMIZED METHOD FOR OBTAINING ACE ACTIVITY INHIBITORY PEPTIDES FROM WHEY, ACE INHIBITORY PEPTIDES AND FOOD COMPRISING THEM - An optimized method for obtaining ACE activity inhibitory peptides includes the steps of whey ultrafiltration for obtaining a whey concentrate, enzymatic hydrolysis, hydrolysate ultrafiltration and inhibitory peptide separation. The method includes selecting and adding a mixture having suitable proportion and amount of two microbial proteases and having complementary action to the whey concentrate for the hydrolysis thereof in order to obtain peptides with an ACE inhibition percentage greater than 70% and an IC | 12-20-2012 |
20130012453 | Acceleration Of Wound Healing By A Tissue Inhibitor Of Metalloproteinases (TIMP) Linked To Glycosylphosphatidylinositol (GPI)-Anchors - The present invention relates to fusion constructs of glycosylphosphatidylinositol (GPI)-anchored tissue inhibitors of metalloproteinases (TIMPs) and their use for the treatment of cancer and in regenerative medicine. By this approach, the GPI-anchored TIMP proteins are incorporated into the surface membrane of cells. The fusion constructs of the present invention are effective agents in accelarating wound healing. | 01-10-2013 |
20130072440 | CO-CRYSTALS AND PHARMACEUTICAL FORMULATIONS COMPRISING THE SAME - The pharmaceutical composition including a co-crystal. The co-crystal includes a) a co-former; and b) an active pharmaceutical ingredient (API) with solubility in water is less than one part by weight of the API in ten parts by weight of water. Furthermore, the formulation includes a polymer, and a weight ratio of the co-crystal to the polymer is about 0.5:99.5 to about 99.5:0.5. The kinetic solubility of the co-crystal after being in contact with an environment of use is at a therapeutically acceptable level for a prolonged period of time. | 03-21-2013 |
20130072441 | Protease Inhibitors and Preventives or Remedies for Disease | 03-21-2013 |
20130096067 | DROSOPHILA TUMOR STEM CELL MODEL AND USES THEREOF - The present invention provides a transgenic | 04-18-2013 |
20130096068 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX - A combination therapy is disclosed for treating cancer. The method comprises identifying a patient diagnosed of cancer and in need of treatment, administering to a cancer patient a therapeutically effective amount of a compound of Formula (I), and administering to said patient a therapeutically effective amount of a proteasome inhibitor. | 04-18-2013 |
20140031297 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 01-30-2014 |
20140045770 | OLIGOMER-PROTEASE INHIBITOR CONJUGATES - The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer. | 02-13-2014 |
20140045771 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) COMPOUNDS - The present invention is directed to novel compounds of formula I and pharmaceutically acceptable salts, enantiomers thereof having inhibiting properties of dipeptidyl peptidase IV enzyme (DP-IV inhibitors). The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds along with its composition in the prevention or treatment of diseases associated with DP-IV enzyme. | 02-13-2014 |
20140100173 | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof - The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions such as cancer. | 04-10-2014 |
20140148395 | PROTEASE TRIGGERED RELEASE OF MOLECULES FROM HYDROGELS - The invention relates to compositions comprising (i) biocompatible hydrogel and (ii) one or more therapeutic agents contained within said hydrogel; wherein the hydrogel is cross-linked utilizing a cross-linker comprising a peptide sequence that is capable of being degraded by an enzyme; the therapeutic agent being effective as a treatment of a condition related to the presence of the enzyme. | 05-29-2014 |
20140315826 | POLYMERIC CONJUGATES OF C-1 INHIBITORS - Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via glycan group of the C1 inhibitor is provided. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided. | 10-23-2014 |
20140349946 | PEPTIDES DERIVED FROM HUMAN BPLP PROTEIN, POLYNUCLEOTIDES CODING FOR SAID PEPTIDES AND ANTIBODIES DIRECTED AGAINST SAID PEPTIDES - The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject | 11-27-2014 |
20160129093 | COMPOSITIONS, METHODS AND USES FOR ALPHA-1 ANTITRYPSIN OR DERIVATIVES THEREOF - Embodiments herein report methods and compositions for treating or preventing adverse effects of radiation therapies. In certain embodiments, compositions and methods relate to reducing or inhibiting damage due to acute, periodic or chronic radiation exposure. | 05-12-2016 |
20160151445 | METHODS FOR THE REGULATION OF MATRIX METALLOPROTEINASE EXPRESSION | 06-02-2016 |
20160168202 | Cyclic peptides as ADAM protease inhibitors | 06-16-2016 |
514200200 | Cysteine protease inhibitor affecting or utilizing | 7 |
20100240577 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 09-23-2010 |
20110230393 | Antibacterial Phage Peptides and Methods of Use thereof - The present invention is directed to isolated and chimeric polypeptides of bacteriophage origin having antibiotic activity and use thereof in the treatment and control of bacterial infections. Specifically, the present invention is directed to the use of a novel antibacterial polypeptide derived from bacteriophage F87s/06 and chimeric constructs thereof, and their use for the treatment and control of infections caused by gram-positive bacteria, including | 09-22-2011 |
20140142024 | BPI AND ITS CONGENERS AS RADIATION MITIGATORS AND RADIATION PROTECTORS - Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy. | 05-22-2014 |
20150344536 | VARIANT OF BPIFB4 PROTEIN - The present invention relates to a variant of BPIFB4 (Bactericidal/Permeability Increasing protein family B, member 4) protein and to its use for the treatment of pathologies involving impairment of nitric oxide signalling. | 12-03-2015 |
20100267644 | Cystatin C as an Antagonist of TGF-BETA and Methods Related Thereto - Disclosed are Cystatin C (CysC) homologues, including CystC homologues that act as antagonists or inhibitors of transforming growth factor-β (TGF-β). Also disclosed are methods to identify CystC homologues that are antagonists or inhibitors of TGF-β and compositions and therapeutic methods using CystC and homologues thereof to regulate the activity of TGF-β, and TGF-β-mediated tumor malignancy and invasion and other TGF-β-mediated fibrotic or proliferative conditions and diseases. | 10-21-2010 |
20110301096 | PRODRUG OF AN ICE INHIBITOR - This invention describes an ICE inhibitor prodrug (I) having good bioavailability. | 12-08-2011 |
20120289469 | METHODS AND COMPOSITIONS FOR MAINTAINING ACTIVE AGENTS IN INTRA-ARTICULAR SPACES - Methods and compositions for maintaining an active agent in an intra-articular space are disclosed. Methods of delivering the compositions to an intra-articular space and methods of making the compositions also are disclosed. The compositions comprise an active agent and a polymer comprising at least one cationic group. A fluid including the composition may be injected into an intra-articular space in a human or animal whereby the composition associates with endogenous material in the intra-articular space. In some embodiments, the fluid further comprises a poorly aqueous soluble polymer. | 11-15-2012 |
20140038902 | Method of Treating Metastatic Cancer - A method of treating metastatic cancer, comprising the steps of (a) treating a metastatic cancer patient with an isolated therapeutic Cystatin C peptide, and (b) observing a reduction in tumor burden is disclosed. | 02-06-2014 |
20140038903 | Selective Cysteine Protease Inhibitors and Uses Thereof - The present invention relates to compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more cysteine proteases. Also described are methods where the compounds of Formula I, II, IA-VA, IVA1-IVA5, IIIA1-IIIA5 are used in the prevention and/or treatment of various diseases and conditions in subjects, including cysteine protease-mediated diseases and/or caspase-mediated diseases such as sepsis, myocardial infarction, cancer, tissue atrophy, ischemia, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative diseases such as multiple sclerosis (MS), ALS, Alzheimer's disease, Parkinson's disease, and Huntington's disease). | 02-06-2014 |
20140288007 | GINGIPAIN INHIBITORY PROPEPTIDES - The disclosure relates to compounds, peptides or peptidomimetics that inhibit, reduce or prevent protease activity and the use of these compounds, peptides or peptidomimetics to treat or prevent a condition. In particular the condition may be periodontal disease. The protease activity may be activity of a gingipain. The compounds, peptides or peptidomimetics of the invention may also be used in assays for the identification of protease inhibitors. | 09-25-2014 |
20150337019 | ANTI-INFLAMMATORY PROTEINS AND PEPTIDES AND METHODS OF PREPARATION AND USE THEREOF - The present disclose relates to anti-inflammatory proteins/peptides, their uses, methods of preparation and methods of their detection. In particular, the invention relates to major royal jelly proteins modified by methylglyoxal and fragments thereof from a | 11-26-2015 |
514200300 | Serine protease inhibitor affecting or utilizing | 24 |
20100273701 | USE OF SALUSIN BETA ALONE OR IN COMBINATION WITH OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ala-lle-Phe-lle-Phe-lle-Arg-Trp-Leu-Leu-Lys-Leu-Gly-His-His-Gly-Arg-Ala-Pro-Pro-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 10-28-2010 |
20100286026 | NOVEL PROTEIN - Provided is a novel, isolated polypeptide including an amino acid sequence of SEQ. ID. NO: 2 or SEQ. ID. NO: 4, and the nucleic acid molecule which encodes it. The polypeptide may be used in a method for treating various diseases including cancer, immune associated, viral and inflammatory diseases. | 11-11-2010 |
20100311645 | PROTEINS FROM THE WEBS OF NEPHILENGYS CRUENTATA, AVICULARIA JURUENSIS AND PARAWIXIA BISTRIATA SPIDERS ISOLATED FROM BRAZILIAN BIODIVERSITY - The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of | 12-09-2010 |
20100331239 | CD14 AND PEPTIDES THEREOF FOR PROTECTION OF CELLS AGAINST CELL DEATH - Provided is a method of using soluble CD14 or peptides derived therefrom for protecting cells from death, specifically from apoptotic cell death. Further provided are compositions including CD14 or CD14 peptides and methods for protecting cells, in particular lymphocytes, from apoptotic cell death. The compositions and methods are relevant, in particular, for the treatment of various immune deficiencies associated, for example, with cell transplantation procedures, autoimmune diseases and infectious diseases such as HIV. | 12-30-2010 |
20110034370 | BIS-MET HISTONES - The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit. | 02-10-2011 |
20110039760 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. | 02-17-2011 |
20110053832 | NATURAL ANTIMICROBIAL COMPOSITION - Natural antimicrobials for foods, such as salad dressings and dairy products to target a broad spectrum of food emulsion spoilage microorganisms such as lactic acid bacteria and fungi such as general yeast and even acid-tolerant yeast (such as | 03-03-2011 |
20110053833 | SYNTHETIC PEPTIDES AND THEIR USE - At least one embodiment of the present invention relates to new peptides designed based on the sequence of human lactoferrin and to use thereof, in particular for treatment and/or prevention of infections, inflammations, tumours, pain, wounds and/or scars. | 03-03-2011 |
20110077192 | Novel Antibacterial Peptides - The present invention relates to monomeric and multimeric peptidic compounds which have antimicrobial activity, particularly against Gram-positive and Gram-negative bacteria. Further, the present invention refers to compositions comprising said peptidic compounds for medical use, for use as a disinfectant and/or detergent or for use as a preservative. | 03-31-2011 |
20110105383 | METHODS AND COMPOSITIONS FOR STIMULATION OF MAMMALIAN INNATE IMMUNE RESISTANCE TO PATHOGENS - Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR polypeptide or peptide or fragment or derivative or analog thereof to the individual. | 05-05-2011 |
20110105384 | USE OF POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY - The present invention relates to the use of polypeptides related to a | 05-05-2011 |
20110136726 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 06-09-2011 |
20110143996 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE - The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκo core and that can be a CXC, CC, or C class chemokine Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods. | 06-16-2011 |
20110160122 | Polypeptides having Antimicrobial Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 06-30-2011 |
20110190197 | PLANT DERIVED ANTIBIOTIC PEPTIDE RICH IN GLYCINE - The present invention relates to a novel peptide extracted from guava ( | 08-04-2011 |
20110201545 | GEL BASED LIVESTOCK FEED, METHOD OF MANUFACTURE AND USE - A method of making a gel-type livestock feed includes initially forming a feed mixture by mixing feed nutrient components, water, alginate, and a calcium component insoluble in water or a sequestrate to inhibit the calcium component from reacting with the alginate. Once the feed mixture is formed, the calcium component is solubilized or the sequestrates affecting the reactivity between the alginate and the calcium component is removed such that a gel feed is formed that includes a gel matrix containing the feed nutrient components. The gel feed may then be fed to the livestock. In another aspect of the present invention, piglets are weaned by feeding the gel feed for at least seven days directly after weaning. The gel feed may also include protein derived from blood with or without egg protein. | 08-18-2011 |
20110207656 | MUC1, CASPASE-8, and DED-CONTAINING PROTEINS - The disclosure features a variety of compositions and methods for modulating an interaction between MUC1 and caspase-8 and/or an interaction between MUC1 and a DED-containing protein (e.g., an anti-apoptotic DED-containing protein or a pro-apoptotic DED-containing protein). Such methods and compositions are useful for the treatment or prevention of, e.g., a variety of pathological disorders characterized by elevated or decreased levels of apoptosis. Moreover, the compositions and methods are also useful to identify, design, and generate compounds that modulate the interactions. The compounds and/or pharmaceutical compositions containing the compounds can be used in the treatment of disease. | 08-25-2011 |
20110212885 | OPHTHALMIC AND CONTACT LENS SOLUTIONS CONTAINING PEPTIDES AS PRESERVATIVE - A method and a contact lens solution comprising 0.001 to 10 weight percent or a preservative enhancer chosen from the group consisting of: SEQ ID NO.1 and SEQ ID NO. 2; and at least 0.0001 weight percent of a preservative agent, and where the concentration of chloride in said solution is less than 0.2 percent by weight. | 09-01-2011 |
20110218138 | Pharmaceutical composition containing polypeptide fragments of serralysins - The present invention is related to a composition capable of inhibiting the growth of tumoral cells of different histological origins and of activated endothelial cells. The components of said compositions are polypeptide fragments of the serralisins, corresponding to the C-terminal fragment, from the internal metionine trough the end of the molecule, which could be combined among them and optionally with the prodigiosins that potentiate the antitumoral effect of the composition. The prodigiosins in the composition could be at a concentration of 0.1-100 nM. The anti-proliferative action of this composition is mediated by apoptotic mechanism. It's “in vivo” administration has antitumoral, antiangiogenic and protective effect against malignant tumors. | 09-08-2011 |
20110237499 | HYBRID TRIPYRROLE-OCTAARGININE COMPOUNDS AND THEIR USE AS MEDICAMENT IN THE TREATMENT OF CANCER AND MICROBIAL ILLNESSES - Hybrid tripyrrole-octaarginine compounds. Hybrids formed by a tripyrrole group bound to a polyarginine peptide which permit the efficient cellular internalization and promote a greater affinity for the DNA. The method of obtainment and uses thereof. | 09-29-2011 |
20110237500 | CECROPIN-MAGAININ HYBRID PEPTIDES - The present invention relates to a biocidal fusion peptide of SEQ ID NO: 1 or a sequence with at least 90% identity thereto, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide, and use of the peptide in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection. | 09-29-2011 |
20110245148 | ACETIC ACID AND A BUFFER - The present invention relates to a composition comprising: a) 0.01-20% wt/wt acetic acid and b) a physiologically tolerable buffer capable of maintaining acetic acid at a pH in the range of 2-7; and use of such a composition as an antimicrobial agent. | 10-06-2011 |
20110245149 | METHODS TO PREVENT AND TREAT DISEASES - This invention discloses methods and compositions that can treat a variety of tissue injuries and infections. Tissue-derived leukocyte chemotactic factors are rapidly released after injury to mammalian tissue and can act as the initial signal leading to the initiation and amplification of acute and chronic inflammation associated with injury and infection. The present invention generally provides methods and compositions to prevent and treat injury of cells, tissue, or organs by blocking or inhibiting the release of leukocyte chemotactic factors, by administering certain effective compositions to the tissue. | 10-06-2011 |
20110269669 | SELF-DECONTAMINATING COATINGS CONTAINING ANTIMICROBIAL PEPTIDES - Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from | 11-03-2011 |
20110288006 | Peptides and methods for inducing cell death - The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or conjugate described herein. In some aspects, the method can be used in the diagnosis, prevention, or treatment of a disease, such as an infection, cancer, autoimmune disease, or inflammatory disease. | 11-24-2011 |
20110301076 | ANTIMICROBIAL COMPOUNDS - The present invention relates to a compound of formula (I) AA-AA-AA-R | 12-08-2011 |
20110319319 | ANTIMICROBIAL KINOCIDIN COMPOSITIONS AND METHODS OF USE - The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γ | 12-29-2011 |
20120004159 | POLYPEPTIDES HAVING ANTIMICROBIAL ACTIVITY AND POLYNUCLEOTIDES ENCODING SAME - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 01-05-2012 |
20120015869 | ANTIMICROBIAL AQUEOUS SOLUTION AND ITS PREPARATION METHOD - The antimicrobial aqueous solution of the present invention comprises an original undiluted aqueous solution containing: 25 μg/ml to 50 μg/ml of an amphipathic preservative comprising a monoglycerol monolaurate; and 12.5 μg/ml to 30 μg/ml of an ε-polylysine. In preparing the antimicrobial aqueous solution, dissolution of the amphipathic antimicrobial can be promoted by addition of a sucrose monolaurate and by heating to 35° C. to 60° C. This antimicrobial aqueous solution can be used effectively, even within a range of concentrations lower than concentrations to be typically used for amphipathic antimicrobials. It is possible to adopt a diglycerol monolaurate, instead of the monoglycerol monolaurate. | 01-19-2012 |
20120028882 | METHOD FOR REMOVING ENDOTOXIN FROM PROTEINS - Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing. | 02-02-2012 |
20120046220 | PHOSPHOLIPID DEPOT - The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same. | 02-23-2012 |
20120065125 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 03-15-2012 |
20120083439 | Method of Preparing Water-Soluble and Biodegradable Antimicrobial Agent - A method of preparing a water-soluble and biodegradable antimicrobial agent is provided. The method includes treating a polypeptide compound with sodium hypochlorite for at least 1 min, such that the polypeptide compound has at least one N-halamine group and has good antimicrobial effect. By using the method of the present invention, a chemical synthesis process is not required and an organic solvent is not required either, and thus, an antimicrobial agent having high water solubility, biodegradability, non-toxicity, good sterilization effect, and regeneration can be prepared with reduced harms to the environment. | 04-05-2012 |
20120083440 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 04-05-2012 |
20120108496 | SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST - The present invention provides novel short-chain peptides, which primarily act as parathyroid hormone (PTH/PTH-1) receptor agonist. These short-chain peptides exhibit increased stability to proteolytic cleavage. Most of short-chain peptides were found to be stable in rat plasma up to 24 hours (in vitro), showed increased stability against GIT enzymes such as pepsin and acidic stomach pH and also against liver microsomes (in vitro). Due to increased metabolic stability, other than parenteral route of administration, some of the short-chain peptides can also be delivered by oral routes of administration, for the treatment/prevention of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, postmenopausal osteoporosis and for stimulating bone repair. A-Z | 05-03-2012 |
20120108497 | COMPOSITIONS FOR CONFERRING TOLERANCE TO VIRAL DISEASE IN SOCIAL INSECTS, AND THE USE THEREOF - Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed. | 05-03-2012 |
20120129761 | PREPARATION OF BONE CEMENT COMPOSITIONS - A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising
| 05-24-2012 |
20120157372 | HUMAN MILK PEPTIDES - The present invention provides for novel peptides derived from human milk In aspects of the invention, the peptides are capable, individually or in combination, of evoking an antioxidative stress response, immunomodulation, anti-inflammatory response and anti-pathogenic response. As such the peptides of the invention may be used in food supplements, milk substitutions, infant formula., mother's milk, parenteral nutrition solutions, cell/tissue/organ storage and perfusion solutions and pharmaceutical formulations. | 06-21-2012 |
20120157373 | ANTIMICROBIAL COMPOUNDS HAVING PROTECTIVE OR THERAPEUTIC LEAVING GROUPS - Antimicrobial compounds, such as silanol or alcohol, include a protecting or leaving group that can protect the compound from degradation during the process of preparing a medical device containing the compound or reduce the volatility of the compound relative to its counterpart without the leaving group. Nearly any hydrolysable leaving group may be employed. The leaving group may be an agent that may serve a therapeutic function in addition to protecting or retaining the antimicrobial agents. | 06-21-2012 |
20120214731 | COMPOUND WS 727713 - The present invention relates to a new compound useful as a modulator of melanocortin receptors. In particular, the present invention relates to a compound WS727713, a process for production of the compound by culturing, in a culture medium, a WS727713-producing strain belonging to | 08-23-2012 |
20120220518 | THERAPEUTIC AGENT DELIVERY SYSTEM AND METHOD - A therapeutic agent delivery system includes a therapeutic agent delivery platform and a therapeutic guest agent. The therapeutic agent delivery platform is capable of being implanted in a tissue being treated. The platform includes a substrate and at least one host molecule coupled to the substrate. The therapeutic guest agent is capable of reversibly coupling with the host molecule when administered to the tissue being treated. The reversible coupling is defined by the binding affinity between the host molecule and the therapeutic guest agent. The therapeutic guest agent is delivered at a rate determined by the affinity release rate between the host molecule and the therapeutic guest agent. The degradation rate of the therapeutic guest agent may be slower than the affinity release rate between the host molecule and the therapeutic guest agent. | 08-30-2012 |
20120231995 | USE OF PYRROLOQUINOLINE COMPOUNDS TO KILL CLINICALLY LATENT MICROORGANISMS - There is provided the use of compounds of formula I | 09-13-2012 |
20120258906 | USE OF PEPTIDES AS ANTIDANDRUFF AGENTS - The present invention relates to compositions comprising peptides with antidandruff activity. The invention also relates to the use of these peptides as antidandruff agents, or in methodes for treating dandruff. | 10-11-2012 |
20120270772 | LIPOPEPTIDE COMPOSITIONS AND RELATED METHODS - The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose. | 10-25-2012 |
20120283171 | MODIFIED BOVINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified bovine somatotropin polypeptides and uses thereof are provided. | 11-08-2012 |
20120283172 | MODIFIED PORCINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES - Modified porcine somatotropin polypeptides and uses thereof are provided. | 11-08-2012 |
20120289454 | METALLODRUGS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES, AND METHODS OF MANUFACTURE AND USE THEREOF - It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target. | 11-15-2012 |
20120309676 | Lantibiotic Salts - Described are certain salts of certain lantibiotic compounds, pharmaceutical compositions comprising the same and use of the salts and compositions for the treatment of microbial infection, particularly Methicillin-resistant | 12-06-2012 |
20120316102 | ANTIMICROBIAL PEPTIDES OF THE CECROPIN FAMILY AND THERAPEUTIC USES THEREOF - The present invention relates to an antimicrobial peptide characterised in that said peptide includes the sequence SEQ ID No. 1 or the sequence SEQ ID No. 2, the sequence SEQ ID No. 2 representing a fragment of the sequence SEQ ID No. 1, for use as a drug. Advantageously according to the invention, the peptide having sequence SEQ ID No. 1 is used specifically for treating bacterial, viral and/or parasitic infections, and the peptide having sequence SEQ No. 2 is used for treating bacterial and/or viral infections. | 12-13-2012 |
20130029900 | NOVEL MAYTANSINOID DERIVATIVES WITH PEPTIDE LINKER AND CONJUGATES THEREOF - The invention relates to novel cell-binding agent-cytotoxic agent conjugate having a peptide linkers and more specifically to conjugates of formula (I). The invention also provides novel cytotoxic agents of formula (II), linker compounds represented by formula (III), and drug-linker compounds represented by formula (IV). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 01-31-2013 |
20130029901 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH - Bone targeted compounds and methods are provided. Compounds can include a Bone Targeting Portion (R | 01-31-2013 |
20130035283 | ENGINEERED OPSONIN FOR PATHOGEN DETECTION AND TREATMENT - The present invention provides for engineered molecular opsonins that may be used to bind biological pathogens or identify subclasses or specific pathogen species for use in devices and systems for treatment and diagnosis of patients with infectious diseases, blood-borne infections or sepsis. An aspect of the invention provides for mannose-binding lectin (MBL), which is an abundant natural serum protein that is part of the innate immune system. The ability of this protein lectin to bind to surface molecules on virtually all classes of biopathogens (viruses, bacteria, fungi, protozoans) make engineered forms of MBL extremely useful in diagnosing and treating infectious diseases and sepsis. | 02-07-2013 |
20130059772 | Use of Repeat Sequence Protein Polymers in Personal Care Compositions - The present invention provides personal care compositions, and more particularly, personal care compositions comprising a bioactively effective amount of a repeat sequence protein polymer. In some particularly preferred embodiments, the present invention provides personal care compositions comprising an effective amount of at least one fragment of a repeat sequence protein polymer having bioactivity. | 03-07-2013 |
20130065818 | Arylamide Compounds And Compositions And Uses Thereof - The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals. | 03-14-2013 |
20130072422 | COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 03-21-2013 |
20130116167 | ANTI-MART-1 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE - The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR. | 05-09-2013 |
20130150284 | IMMOBILIZED BIOLOGICALLY ACTIVE ENTITIES HAVING A HIGH DEGREE OF BIOLOGICAL ACTIVITY - The present invention relates to immobilized biologically active entities having heparin cofactor II binding activity. | 06-13-2013 |
20130157930 | LINEAR POLYESTERAMIDES FROM AMINOPHENOLIC ESTERS - The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by | 06-20-2013 |
20130165368 | ANTIMICROBIAL COMPOUNDS - A composition for use in the prevention and/or treatment of microbial infection comprising essentially of one or more pure alkanol alkoxylates, diol alkoxylates and/or triol alkoxylates. | 06-27-2013 |
20130172235 | ORAL TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin. | 07-04-2013 |
20130172236 | METHODS FOR EXTRACTING PLATELETS AND COMPOSITIONS OBTAINED THEREFROM - This invention provides methods for extracting platelets, compositions obtained therefore, and methods for using the same. | 07-04-2013 |
20130210705 | METALLODRUGS HAVING IMPROVED PHARMACOLOGICAL PROPERTIES AND METHODS OF MANUFACTURE AND USE THEREOF - It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (“AMP”) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms. | 08-15-2013 |
20130210706 | DENDRIMERIC PEPTIDES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME - Novel peptide compounds and pharmaceutical compositions thereof are disclosed that have a formula represented by the following formula (I) wherein L | 08-15-2013 |
20130217618 | NUCLEIC AND AMINO ACID SEQUENCES FOR THE CONTROL OF PATHOGEN AGENTS - The present invention reveals a nucleic acid sequence from | 08-22-2013 |
20130225481 | ANTIMICROBIAL PEPTIDES - The present invention relates to antimicrobial peptides, to their use as antimicrobial agents and to their use in the treatment of (infectious) diseases, in particular infectious diseases caused by Gram-positive bacteria, Gram-negative bacteria, yeast or fungi. The present invention further relates to pharmaceutical compositions and kits comprising the antimicrobial peptides and to a method of lysing bacterial, yeast or fungal cells. The antimicrobial peptides consist of one of the following general formula: Wherein X is a hydrophobic amino acid, Y is a cationic amino acid, Z is an amino acid having a free thiol or thioether group, n is 2-4 and m is 0 or 1. | 08-29-2013 |
20130281359 | NEW BICYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND BETA-LACTAMASE INHIBITORS - A compound of formula (I): | 10-24-2013 |
20130288951 | COMPOSITIONS AND METHODS FOR COATING IMPLANT SURFACES TO INHIBIT SURGICAL INFECTIONS - Infection-inhibiting compositions suitable for coating surfaces of implantable medical implants, including compositions and devices for coating medical devices in the operating room prior to implantation in a patient. Methods for inhibiting infection at the site of implantation of an orthopedic device in a human or animal subject, comprise rubbing a surface of the device, prior to implantation, with an infection-inhibiting composition having a waxy matrix comprising an infection-inhibiting material selected from the group consisting of a lipid, an antimicrobial agent, and mixtures thereof, wherein a thin layer of the infection-inhibiting material is deposited on the surface of the device. Medical implants which may be treated in the methods of this technology include orthopedic implants. Lipids include long-chain diacylglycerides or triacylglycerides, which may be saturated or unsaturated, such as lecithin or a purified form of phosphatidylcholine. | 10-31-2013 |
20130303437 | ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS - The disclosure provides a molecular genetic approach of targeted mutagenesis and heterologous expression, coupled with in vitro and in vivo models of bacterial pathogenesis, to demonstrate that the | 11-14-2013 |
20130345118 | MATRIX SCAFFOLD WITH ANTIMICROBIAL ACTIVITY - The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides. | 12-26-2013 |
20140051625 | Bone Targeted Therapeutics and Methods of Making and Using the Same - The present invention provides novel bisphosphonate conjugates, pharmaceutical compositions comprising bisphosphonate conjugates and methods of using such analogs in the treatment of bone cancer, bone-related diseases, bone infection, bone inflammation, and diseases of the soft tissues surrounding bones. | 02-20-2014 |
20140066362 | METHOD FOR TREATING INFECTIONS BY TARGETING MICROBIAL H2S-PRODUCING ENZYMES - The invention provides materials and methods for treating infections by reducing endogenous microbial H | 03-06-2014 |
20140142025 | Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent - The disclosure describes collagen constructs comprising antimicrobial agents and related methods. | 05-22-2014 |
20140142026 | Anti-Pathogen Treatments - Chimeric molecules that contain at least one pathogen-detection domain and at least one effector domain, and their methods of use in preventing or treating a pathogen infection in a cell or organism are described. The pathogen-detection domain and effector domain of the chimeric molecules are domains not typically found in nature to be associated together. Agents are also described herein having at least one pathogen-interacting molecular structure and at least one effector-mediating molecular structure, the agent being one that is non-naturally-occurring in a cell. The methods of prevention and treatment described herein are effective for a broad spectrum of pathogens and exhibit little or no toxic side-effects. Assays for the detection of a pathogen, pathogen component, or product produced or induced by a pathogen, are also provided. | 05-22-2014 |
20140142027 | MULTIMERIC FORMS OF ANTIMICROBIAL PEPTIDES - The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3. The method includes a composition or combination comprising the multimeric antimicrobial peptides and at least one active pharmaceutical ingredient. | 05-22-2014 |
20140155317 | SELECTIVELY TARGETED ANTIMICROBIAL PEPTIDES AND THE USE THEREOF - The present invention relates to targeting peptides capable of specifically binding to microbial organisms (e.g., | 06-05-2014 |
20140179593 | METHODS AND COMPOSITIONS FOR INHIBITING NEDDYLATION OF PROTEINS - Provided herein is a novel binding pocket within NEDD8 co-E3 proteins that binds NEDD8 E2 enzymes. Particularly at its M-Terminus. Methods are provided for screening for compounds that bind to the disclosed E2-binding pocket in NEDD8 co-E3 proteins. Compounds that bind to the E2-binding pocket and optionally inhibit the activity of NEDD8 co-E3 proteins and pharmaceutical compositions comprising the same are further provided. The NEDD8 co-E3 inhibitors find use, as agents preventing the NEDDylation of a target protein, in inhibiting cell growth and methods for treating cancers, inflammatory disorders, and pathogenic infections. The preferred inhibitors are peptides corresponding to a M-terminal fragment of Dnc1, e.g. MTLASKLKRDD, MLKLRQLQKKKQ, and MIKLFSLKQQKK, which are substituted at the M-Terminus with an uncharged group (e.g. acyl). | 06-26-2014 |
20140235530 | Spray Drying Vancomycin - A method and formulation for preparing spray dried vancomycin. In various embodiment, the formulation includes vancomycin HCl (10-20%) and one or more of the following PEG (0-5%), mannitol (0-5%), ethanol (0-10%), and a citrate buffer. Spray dried vancomycin has favorable reconstitution times and water content. | 08-21-2014 |
20140249073 | BROAD SPECTRUM ANTIBIOTICS - Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. The compounds provided herein can in other embodiments overcome the resistance conferred by single amino acid mutations at defined positions of bacterial Signal Peptidases (SPases) and in other embodiments provide for a broader spectrum of antibiotic bioactivity compared to the natural product. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided. | 09-04-2014 |
20140256612 | ANTIBIOTIC CONJUGATES DIRECTLY LINKED WITH STEROID DRUGS - The present invention describes novel single drug entities, formed by direct linkage of an antibiotic to a steroidal drug. Upon topical application to the eye, the conjugate would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. The antibiotic is coupled directly to the steroid drug. | 09-11-2014 |
20140256613 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed. | 09-11-2014 |
20140274875 | Hemostatic Compositions And Methods - Compositions and methods for achieving hemostasis. Hemostatic compositions comprise a phospholipid, and optionally, an anti-infective agent. The hemostatic composition can be administered to a bleeding bone to achieve hemostasis. | 09-18-2014 |
20140287987 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 09-25-2014 |
20140303069 | Anti-Microbial Peptides and Methods of Use Thereof - Anti-microbial peptides and methods of use are provided. | 10-09-2014 |
20140309159 | COMPOSITIONS AND METHODS FOR TARGETING NUCLEAR IMPORT SHUTTLES AND TREATING INFLAMMATORY DISORDERS - The present invention relates to compositions and methods for treating autoimmune, microbial, metabolic, neoplastic, and posttraumatic diseases mediated by inflammation in a subject. Compositions and methods including at least one importin beta-selective nuclear transport modifier (NTM) and/or at least one importin alpha-selective NTM, and/or at least one importin alpha-specific NTM, and/or at least one inhibitor of importin alpha and importin beta complex formation may be administered to a subject to modulate the transport of transcription factors, mediated by nuclear import adaptors, into the nucleus of a cell resulting in a decrease or abrogation of inflammation. | 10-16-2014 |
20140309160 | PLANT DISEASE CONTROL AGENT - The present invention relates to a plant disease control agent containing a compound represented by the following formula (1) or salt thereof as an active ingredient (in the formula, R | 10-16-2014 |
20140349917 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 11-27-2014 |
20150031600 | DESIGNED BIOSURFACTANTS, THEIR MANUFACTURE, PURIFICATION AND USE - The present invention relates to designed polypeptide biosurfactants that may be prepared by recombinant technology in commercially useful amounts and purified by simple non-chromatographic methods. The designed polypeptide biosurfactants comprise at least one stimuli-responsive amino acid residue or at least one glutamine or asparagine residue and may be useful in modulating the stability of a foam, alone or in combination with an α-helical peptide. The designed polypeptide biosurfactant may be useful in the formation and collapse of foams in foods, beverages, pharmaceuticals, personal care products, cosmetics, cleaning products, mineral recovery, bioremediation, oil recovery and laundry products. The designed biosurfactants may also be useful in recombinant production and purification of peptides, polypeptides and proteins. | 01-29-2015 |
20150031601 | Antimicrobial Peptide Variants and Polynucleotides Encoding Same - The present invention relates to variants of a parent antimicrobial peptide. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 01-29-2015 |
20150038406 | PHARMACEUTICAL FORMULATIONS OF TRANEXAMIC ACID AND THEIR USE - The present invention relates to pharmaceutical formulations comprising tranexamic acid, kits thereof, and methods for treating bleeding by local administration. | 02-05-2015 |
20150080290 | COMPOSITIONS AND USES OF ANTIMICROBIAL MATERIALS WITH TISSUE-COMPATIBLE PROPERTIES - Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken. | 03-19-2015 |
20150094255 | Lectin Conjugates for Mucin Hydration - The invention provides, inter alia, conjugates of a hydratable polymer (such as PEG, polyethylene glycol) and a lectin (such as wheat germ agglutinin, WGA), compositions comprising these conjugates, as well as methods and targeted uses of these conjugates and compositions for, e.g., lubricating, maintaining hydration of rehydrating, and/or inhibiting microorganism colonization of a biological surface in need thereof. | 04-02-2015 |
20150094256 | USE OF THE CATHELICIDIN LL-37 AND DERIVATIVES THEREOF FOR WOUND HEALING - Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37. | 04-02-2015 |
20150141323 | PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USE - The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof. | 05-21-2015 |
20150148285 | SALT AND PROTEASE-RESISTANCE OF ANTIMICROBIAL PEPTIDE AND THE MANUFACTURE THEREOF - The present invention provides an antimicrobial peptide, wherein the amino terminal and/or carboxyl terminal of the peptide is linked with at least one artificial bulkyl amino acid to increase the salt resistance and protease resistance of the antimicrobial peptide. The antimicrobial peptide of the invention has a high salt resistance, a high protease resistance, and a low hemolytic activity, simultaneously. | 05-28-2015 |
20150306173 | PHOSPHOLIPID DEPOT - The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same. | 10-29-2015 |
20150313960 | NOVEL DEPSIPEPTIDE AND USES THEREOF - The present invention relates generally to novel depsipeptides, to methods for the preparation of these novel depsipeptides, to pharmaceutical compositions comprising the novel depsipeptides; and to methods of using the novel depsipeptides to treat or inhibit various disorders. | 11-05-2015 |
20150328283 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents, which include a plurality of positively charged amino acid residues and at least one omega-amino-fatty acid residue linking therebetween, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 11-19-2015 |
20150329607 | MUTANT NGAL PROTEINS AND USES THEREOF - In one aspect the present invention is directed to mutant NGAL proteins that have the ability to bind to siderophores, such as enterochelin, and to chelate and transport iron, and that are excreted in the urine. Such NGAL mutants, and complexes thereof with siderophores, can be used to clear excess iron from the body, for example in the treatment of iron overload. The NGAL mutants of the invention also have antibacterial activity and can be used in the treatment of bacterial infections, such as those of the urinary tract. | 11-19-2015 |
20150343014 | TOPICAL ANTIMICROBIAL DERMATOLOGICAL COMPOSITION - The invention relates to a composition that may be used in dermatology. | 12-03-2015 |
20150359844 | ANTIMICROBIAL BACTERIA STRAINS AND USES THEREOF - The present invention provides novel antimicrobial bacteria strains and uses thereof to prepare novel antimicrobial agents. Also provided are the novel antimicrobial agents. | 12-17-2015 |
20150366193 | COMPOSITION WITH HIGH ANTIMICROBIAL ACTIVITY AND LOW TOXICITY - Improved synthetic copolypeptide antimicrobials contain cationic amino acid residues and may be based on a blocky sequence. These antimicrobials show low mammalian toxicity and may undergo directed self-assembly. The inventive synthetic copolypeptides are useful in treatment of wounds and other infections. | 12-24-2015 |
20160000079 | Novel small molecule inhibitors of biofilm formation and the novel use of previously identified compounds for inhibition of biofilm formation and applications for drug therapy and medical device coating - Novel compounds and the novel use a class of previously identified small molecules for the inhibition of biofilm formation. Inhibition of biofilm formation can play a very important role in contributing to pathogenicity. Bacteria in the biofilm state have been shown to be 10-10,000-fold less susceptible to antibiotic treatment. Estimations made by the Centers for Disease Control (CDC) and the National Institutes of Health (NIH) attribute 65% to 80% of human infections as biofilm mediated. Consequently, biofilm formation is often responsible for chronic infections due to bacterial persistence despite antibiotic treatment. | 01-07-2016 |
20160000924 | METHODS FOR PRODUCING A BIODEGRADABLE CHITOSAN COMPOSITIONS AND USES THEREOF - The invention provides improved methods for generating biodegradable chitosan compositions, and therapeutic methods of using such compositions to deliver therapeutic agents. | 01-07-2016 |
20160038631 | Acrylic Cements for Bone Augmentation - The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component. | 02-11-2016 |
20160060298 | BETA-HAIRPIN PEPTIDOMIMETICS - Beta-hairpin peptidomimetics of the general formula (I), cyclo(P | 03-03-2016 |
20160082114 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. | 03-24-2016 |
20160090571 | CULTURE MEDIA AND METHODS FOR CULTURING MICROORGANISMS - Methods and culture media for culturing a microorganism associated with Morgellons disease are provided. In exemplary embodiments, methods are provided that may include adding a microorganism associated with Morgellons disease to a solution containing ferrous iron, sugar and water or to a solid growth medium containing agar and ferrous iron. Also provided are compositions containing a microorganism associated with Morgellons disease as well as methods for isolating lipids and proteins from this microorganism and methods for inhibiting its growth. | 03-31-2016 |
20160114002 | COMPOSITIONS COMPRISING PLANT PROTEINS AND METHODS FOR PREVENTION OF METABOLIC AND CARDIOVASCULAR PATHOLOGIES IN PATIENT WITH CARDIOMETABOLIC RISK, INCLUDING HYPERGLYCEMIA - A composition for oral administration in humans comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture thereof, and:
| 04-28-2016 |
20160137599 | 2-METHYLTHIOPYRROLIDINES AND THEIR USE FOR MODULATING BACTERIAL QUORUM SENSING - Compounds of Formula (I) are disclosed herein and their use in inhibiting quorum sensing in bacteria. | 05-19-2016 |
20160184448 | CROSS-LINKED COLLAGEN WITH AT LEAST ONE BOUND ANTIMICROBIAL AGENT FOR IN VIVO RELEASE OF THE AGENT - The disclosure describes collagen constructs comprising antimicrobial agents and related methods. | 06-30-2016 |
20160199447 | LIPID NANOPARTICLES FOR WOUND HEALING | 07-14-2016 |
20160200770 | SUBSTITUTED UREA DEPSIPEPTIDE ANALOGS AS ACTIVATORS OF THE CLPP ENDOPEPTIDASE | 07-14-2016 |
20160376738 | ELECTROPROCESSED BIOFUNCTIONAL COMPOSITION - Described are methods for preparing an electroprocessed composition functionalized with bioactive materials and the use of the electroprocessed composition, including use as an engineered extracellular microenvironment and its use in forming three-dimensional matrix for biological application. The electroprocessed composition may also be combined with other molecules in order to deliver substances to the site of application or implantation of the electroprocessed composition. | 12-29-2016 |
20170231228 | SURFACE TREATMENTS | 08-17-2017 |
20120094931 | COMPOSITIONS AND METHODS TO MODULATE PROGRESSION AND ONSET OF INFLAMMATORY BOWEL DISEASE - Embodiments herein illustrate methods and compositions for treating inflammatory bowel disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or modulating progression of an inflammatory bowel disorder in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin. | 04-19-2012 |
20120309693 | Methods to Accelerate Tissue and Wound Healing Rates and Reduce Swelling and Scar Formation - The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor. | 12-06-2012 |
20130079289 | Pharmaceutical Compositions - Forms and formulations of VX-950 and uses thereof. | 03-28-2013 |
20130316960 | Novel Peptides For Treating and Preventing Immune-Related Disorders, Including Treating And Preventing Infection by Modulating Innate Immunity - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention. | 11-28-2013 |
20140296157 | COMPOSITIONS AND METHODS FOR PREPARING A SUBJECT FOR ORGAN OR NON-ORGAN IMPLANTATION - Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery. | 10-02-2014 |
20140309175 | POLYMERIC CONJUGATES OF C1-INHIBITORS - Polymer conjugates containing a C1-inhibitor having at least one substantially non-antigenic polymer covalently attached to the C1-inhibitor via thiol group of the C1 inhibitor is provided. In the polymer conjugates of the present invention, the substantially non-antigenic polymer is attached to either free thiol from a cysteine of thiol generated from disulfide bonds in C1 inhibitor. Alternatively, the substantially non-antigenic polymer is attached to one of more thiols in C1 inhibitor via bifunctional spacer. In addition, methods of making the conjugates as well as methods of treatment using the conjugate of the present invention are also provided. | 10-16-2014 |
20150057232 | Anti-Inflammatory Composition for Modulating the Cell Response of Neutrophils and Eosinophils - The present invention relates to an anti-inflammatory composition intended for humans and animals for modulating the cell response of the neutrophils and of eosinophils. | 02-26-2015 |
20160008442 | TREATMENT AND PREVENTION OF REMOTE ISCHEMIA-REPERFUSION INJURY | 01-14-2016 |
20160083430 | PEPTIDE AND PEPTIDOMIMETIC INHIBITORS - The present invention provides inhibitors and/or antagonists of plasma kallikrein. Also provided are methods of utilizing the inhibitors as therapeutics. | 03-24-2016 |
20160184437 | Polymer, and pharmaceutical composition employing the same - A polymer and a pharmaceutical composition employing the same are disclosed. The polymer includes a first repeating unit, a second repeating unit, and a third repeating unit. In particular, the first repeating unit is | 06-30-2016 |
20160199466 | Methods For Treating Tissue Fibrosis | 07-14-2016 |
20170232081 | METHODS FOR TREATMENT OF AND PROPHYLAXIS AGAINST INFLAMMATORY DISORDERS | 08-17-2017 |
514200400 | Elastase inhibitor affecting or utilizing | 12 |
20100267621 | Antimicrobial Compounds and Formulations - The invention relates to the use of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto at least two bulky and lipophilic groups and having at least one more cationic than anionic moiety, in the manufacture of a medicament for destabilising microbial cell membranes and the use as a membrane acting antimicrobial agent of a molecule comprising a backbone of 2 to 35 non-hydrogen atoms in length, having covalently attached thereto a super bulky and lipophilic group comprising at least 9 non-hydrogen atoms and having at least two more cationic than anionic moieties and to methods of treatment involving such molecules, in particular peptides including peptide derivatives, and peptidomimetics. | 10-21-2010 |
20100267622 | Methods to activate or block the HLA-E/Qa-1 restricted CD8+ T cell regulatory pathway to treat immunological disease - Methods are provided for inhibiting or enhancing down-regulation of an antigen-activated HLA-E+ T cell by an HLA-E-restricted CD8+ T cell comprising contacting the HLA-E* T cell and CD8+ T cell with an agent which inhibits or enhances, respectively, binding between (i) T cell receptor (TCR) on the surface of the CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of the HLA-E+ T cell, thereby inhibiting or enhancing, respectively, down-regulation of the antigen-activated HLA-E+ T cell. Compositions comprising agents which inhibit or enhance/activate, respectively, binding between (i) T cell receptor (TCR) on the surface of a CD8+ T cell and (ii) a self peptide presented by HLA-E on the surface of a HLA-E+ T cell, and assays for identifying such agents, are provided. | 10-21-2010 |
20100267623 | PEPTIDES WITH CAPACITY TO BIND TO SCURFIN AND APPLICATIONS - The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X | 10-21-2010 |
20100286027 | ANTI-BACTERIAL COMPOSITIONS - The invention relates to an isolated protein for use as an antimicrobial agent comprises a plurality of LRR (leucine rich repeat) domains, each LRR domain independently comprising an amino acid sequence of formula (I): (F1LxxLxL(xxZ) | 11-11-2010 |
20100292135 | INHIBITORS OF RecA ACTIVITIES FOR CONTROL OF ANTIBIOTIC-RESISTANT BACTERIAL PATHOGENS - Compounds for modulating RecA protein activity are provided. In some embodiments, the compounds modulate RecA activity by interfering with assembly of monomeric RecA protein subunits into a nucleoprotein filament. In some embodiments, the compounds modulate RecA activity by interfering with adenosine triphosphate hydrolysis by the RecA protein. Methods of screening for and methods of using the compounds are also provided. | 11-18-2010 |
20100298206 | HYBRID OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to compositions and methods for producing therapeutic oligomeric compounds. In one aspect the invention relates to methods for administering the oligomeric compounds for the treatment and prevention of disease, for example, a fungal infection, bacterial infection, or cancer, in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, pharmacologically active agent or a combination thereof. | 11-25-2010 |
20100298207 | PESTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a toxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated toxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:50-96, or the nucleotide sequence set forth in SEQ ID NO:1-47, as well as variants and fragments thereof. | 11-25-2010 |
20100305025 | RNASE A PEPTIDES, FRAGMENTS AND USES THEREOF - The present invention features isolated polypeptides that have bactericidal and angiogenic activities. The invention features isolated polypeptides comprising amino acid sequences of RNase A ribonucleases, fragments and variants thereof, pharmaceutical compositions, and methods for treatment of a subject. | 12-02-2010 |
20100331240 | METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND FICOLIN-MBL FUSION PROTEINS - The present invention provides methods of treatment and/or prevention of infections, for example, viral and bacterial infections, in individuals, wherein the method comprises administering a supraphysiological amount of mannose-binding lectin (MLB) and/or ficolin-MBL fusion protein to an individual afflicted with an infection or at risk of an infection, such as a bacterial or a viral infection. For example, methods for treatment and/or prevention of Ebola virus infection are provided. | 12-30-2010 |
20110021414 | Chimeric Phage Tail Proteins and Uses Thereof - A multi-protein pyocin-like structure derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber having a protein receptor binding domain capable of recognizing Lipid A. A multiprotein pyocin-like structure, derived from a bacteriophage or a bacteriocin that includes a chimeric tail fiber capable of recognizing and binding MurNac-L-Ala-D-Glu. A phage including a chimeric tail fiber that binds Lipid A. A plasmid encoding a chimeric ail fiber that binds MurNac-L-Ala-D-Glu. A plasmid encoding a chimeric tail fiber that binds Lipid A. A chimeric bacteriocin or bacteriophage derived tail fiber that includes the amino terminal of the human bactericidal/permeability-increasing protein (BPINTD)—A chimeric bacteriophage or bacteriocin derived tail fiber also includes a binding domain encoding the mammalian Nod2cτD—An antibacterial agent includes a bacteriocidal/permeability-increasing protein receptor domain that binds to Lipid A. An antibacterial agent also includes Nod2 carboxyl-terminus receptor domain that binds MurNac-L-Ala-D-Glu. | 01-27-2011 |
20110028385 | Combination of Immunomodulator and Anti-Pathogenic Agent - A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals. | 02-03-2011 |
20110034371 | L. CASEI RHAMNOSUS SECRETED FACTORS AND USE THEREOF - The present invention relates to a composition for inhibiting gastrointestinal inflammation comprising an effective amount of | 02-10-2011 |
20110039761 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110039762 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110039763 | TARGETED ANTIMICROBIAL MOIETIES - This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species. | 02-17-2011 |
20110046039 | POST-EXPOSURE PROPHYLAXIS AND TREATMENT OF INFECTIONS - The invention provides methods and materials for identifying agents for preventing and/or treating anthrax and similar diseases. Embodiments provide strains and model systems for studying non-lethal and lethal exposure to anthrax and similar disease vectors. Embodiments provide materials and methods for using the strains and model systems for differential profiling, such as proteomic profiling, such as differentiation phosphorylation profiling, to target identification and therapeutics discovery and development. Embodiments provide pharmaceutically acceptable compositions, and methods for using them to prevent and/or treat anthrax and similar diseases comprising an agent that decreases the activity of caspase ¼, such as YVAD, and/or an agent that increases the phosphorylation of AKT, such as IB-MECA or Cl-IB-MECA, together with, in particular embodiments, an antibiotic, such as ciprofloxacin. Kits comprising the same are provided as well, among other things. | 02-24-2011 |
20110053834 | NOVEL ANTIBIOTIC PEPTIDE DERIVED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE THEREOF - The present invention relates to a new antibiotic peptide and a usage thereof, which are derived from ribosomal protein L1, RPL1 of | 03-03-2011 |
20110053835 | ANTIMICROBIAL PEPTIDES DERIVED FROM CAP18 - The present invention relates to a group of peptidic compounds which have antimicrobial activity. The compounds also have affinity for toxins and especially for bacterial toxins, such as lipopolysaccharide or lipoteichoic acid. The compounds can be used to manufacture medicaments useful for the treatment of bacterial or fungal infections. The medicaments may be administered systemically or locally. | 03-03-2011 |
20110053836 | USE OF DEFENSINS AGAINST TUBERCULOSIS - The present invention relates to a method for killing or inhibiting cells of | 03-03-2011 |
20110065630 | USE OF A OCTREOTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 03-17-2011 |
20110098214 | LPS OR LIPID A BINDING AGENT AND NOVEL PEPTIDE - A lipopolysaccharide (LPS) and/or lipid A binding agent is provided. The LPS and/or lipid A binding agent contains an LPS and/or lipid A binding peptide, such as a peptide comprising an amino acid sequence of XYSSS (X=K, R, or H), or a derivative thereof, as an active ingredient. The LPS and/or lipid A binding agent is useful as, for example, an LPS and/or lipid A neutralizing agent or an LPS and/or lipid A removing agent. | 04-28-2011 |
20110118174 | TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS - A treatment solution used to prevent posterior capsular opacification is applied or introduced into the lens capsular bag before, during, or after cataract surgery. The treatment solution may also be applied to an intraocular lens prior to surgery. The treatment solution comprises an ion transport mechanism interference agent, which either alone or in combination with other treatment agents such as an osmotic stress agent and an agent to establish a suitable pH, selectively induces detachment and/or death of lens epithelial cells such that posterior capsular opacification is prevented. While the ion transport mechanism interference agent is capable of interfering with the cellular mechanisms and cell ion distribution of a broad range of cells, a concentration of agent is selected such that the treatment solution interferes selectively with the cellular mechanisms of lens epithelial cells while leaving other ocular cells substantially unharmed. The treatment solution selectively induces cellular death and/or detachment of lens epithelial cells while other ocular cells and tissue remain substantially unharmed and without lengthy preoperative pre-treatment. | 05-19-2011 |
20110136727 | Compositions and methods for rapid selection of pathogen binding agents - Isolated glycan binding peptide complex comprise two or more glycan binding peptides operatively coupled to each other. These are bacterial binding peptide conjugates (e.g., glycan binding peptides) to a multivalent polymer (e.g., a multivalent PEG molecule) or to the surface of particles that create multimeric constructs that inhibit growth and aggregation of microbes. Included is a method of evaluating a substance for the presence of a microbe comprising contacting the substance with a peptide microarray or a peptide complex comprising a plurality glycan binding peptide operatively coupled to a substrate or multivalent linker, wherein the glycan binding peptide is coupled to an array by a linker that is at least 0.5 micrometers in length. | 06-09-2011 |
20110136728 | METHODS OF INCREASING BONE FORMATION USING LEPTIN-RELATED PEPTIDES - The present invention relates to methods of increasing bone formation in patient suffering from a wasting disorder by orally or intranasally administering a pharmaceutically effective amount of a leptin peptide and a pharmaceutically acceptable carrier, wherein the leptin peptide increases serum osteocalcin levels. | 06-09-2011 |
20110143997 | PHAGE RECEPTOR BINDING PROTEINS FOR ANTIBACTERIAL THERAPY AND OTHER NOVEL USES - The subject invention relates in part to novel uses of bacteriophage tail spike proteins (TSPs). Some preferred uses are therapeutic uses in animals, such as chickens, against pathogenic bacteria, such as Salmonella. Fragments of the TSPs can also be used according to the subject invention, particularly protein fragments comprising the phage receptor binding domains (PRBDs), which recognize their hosts and facilitate infection. The binding domains are specific to unique surface structures on bacteria and may be used for a variety of applications according to the subject invention. We have shown that by utilizing these PRBDs, it is possible to exploit the long-established evolutionary relationship between bacteria and their viruses (ie bacteriophages) that specifically infect them. The subject invention also relates in part to novel, synthetic forms of tail spike proteins. In some preferred embodiments, these are hexamers. | 06-16-2011 |
20110143998 | IDENTIFICATION AND USE OF PEPTIDE INHIBITORS OF PROTEIN SYNTHESIS - The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit. | 06-16-2011 |
20110143999 | FOWLICIDINS AND METHODS OF ITS USE - Antimicrobial peptides and methods for their use are provided. The peptides are optimized, truncated versions of chicken cathelicidins (“fowlicidins”). | 06-16-2011 |
20110144000 | ANTIMICROBIAL POLYPEPTIDE - A molecule has a first isolated peptide as shown in SEQ ID NO: 1 or part thereof or a peptide having at least 78% homology to SEQ ID NO:1 conjugated to a second peptide. The second peptide is an amphipatic peptide with an alpha-helical structure or a linear cationic peptide and the first and second peptides have a length of from about 5 to 100 amino acid residues. The molecule is used in medicine as well as for the manufacturing of a medicament for the treatment of a mammal in need thereof, such as for the treatment of a bacterial disease or disorder. | 06-16-2011 |
20110144001 | HIGHLY BRIDGED PEPTIDES FROM ACTINOMADURA NAMIBIENSIS - The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) | 06-16-2011 |
20110152175 | DENDRIMERIC COMPOUNDS COMPRISING AMINO ACIDS, HYPERBRANCHED CORE COMPOUND, PROCESS FOR PREPARATION OF DENDRIMERIC COMPOUNDS COMPRISING AMINO ACIDS AND HYPERBRANCHED CORE COMPOUND, AND USE THEREOF - The invention provides dendrimeric compounds of the formula 1 comprising amino acids, wherein n is an integer of 1-4, T is an alkylidene —(CH2)2CONH(CH2)2- group, R2 is an —NH2 group or a moiety of a primary organic amine, and P is an amino acid and/or peptide moiety, wherein at least one hydrogen atom of at least one amino group is optionally replaced by a protective group, and a hyperbranched core compound of the formula 3, wherein T and R2 are as defined above. The invention provides also a process for the preparation of a dendrimeric compound and a hyperbranched core, wherein the process employs addition reactions of alkyl acrylate and a basic amino acid, and use of a hyperbranched core for the preparation of a dendrimeric compound comprising amino acids. The invention provides also use of dendrimeric compounds for the preparation of the medicament for inhibiting growth of bacterial cells, fungi and tumor cells. | 06-23-2011 |
20110160123 | TARGETING THE EFFLUX SYSTEMS OF MYCOBACTERIUM TUBERCULOSIS - Provided herein are methods of reducing drug resistance in | 06-30-2011 |
20110190198 | PEPTIDE SEQUNCES, THEIR BRANCHED FORM AND USE THEREOF FOR ANTIMICROBIAL APPLICATIONS - The present invention relates to an antibacterial peptide having from the amino to the carboxylic terminal an amino acid sequences selected from the group of: KKIRVRLSA, SEQ ID NO. 1, RRIRVRLSA, SEQ ID NO. 2, KRIRVRLSA, SEQ ID NO. 3, RKIRVRLSA, SEQ ID NO. 4 or a derivative thereof and uses thereof. | 08-04-2011 |
20110230394 | Processes Using Antibiotic Alternatives In Bioethanol Production - Methods for controlling the growth of bacteria in ethanol fermentation systems with antibiotic alternatives, which can be nonoxidizing biocides, stabilized oxidizers, or any combinations thereof, are described. As an option, a process or composition of the present invention can include one or more polycyclic antibacterial peptides. The methods can provide improvements, such as increased ethanol yields with minimal carryover of biocide into co-products of the processes. | 09-22-2011 |
20110245150 | TARGETS FOR TREATMENT OF CHLAMYDIAL INFECTIONS - The present invention relates to a screening method for identification of a compound suitable for the prevention, treatment or/and diagnosis of an infection with Chlamydiaceae. | 10-06-2011 |
20110245151 | Bacteriocins and Novel Bacterial Strains - Novel bacteriocins produced by novel bacterial strains are used for at least reducing the levels of colonization by at least one target bacteria in animals, especially poultry. | 10-06-2011 |
20110251120 | Antimicrobial Peptides and Methods of Identifying the Same - Antimicrobial peptides and methods of identifying the same are provided. | 10-13-2011 |
20110281787 | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same - The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceutical compositions comprising a combination of an antisense oligonucleotide compound conjugated with a positively charged polymer (“ON-PCP”) and a negatively charged polymer. Pharmaceutical compositions in accordance with the present invention have demonstrated improved antisense efficiency and reductions in cell toxicity compared to compositions that contain an oligonucleotide compound conjugated with a positively charged polymer. | 11-17-2011 |
20110288007 | BIOCIDAL FUSION PEPTIDE COMPRISING LL-37 - The present invention relates to a biocidal fusion peptide comprising: a) a peptide LL-37 or an active fragment or active derivative thereof; b) and a further heterologous bioactive peptide or an active fragment thereof, wherein part or all of the amino acid sequence of the fusion peptide is predicted to form an alpha-helix structure for disruption of a pathogen membrane, compositions such as pharmaceutical compositions comprising the same, methods of preparing the peptide and use of the peptides in treatment, in particular for the treatment of bacterial infection and/or fungal infection and/or viral infection. | 11-24-2011 |
20110312875 | PEPTIDIC COMPOUNDS - The present invention provides a compound of formula I, II, III and IV as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention. | 12-22-2011 |
20120004160 | METHODS FOR IDENTIFYING AND COMPOUNDS USEFUL FOR THE DIAGNOSIS AND TREATMENT OF DISEASES INVOLVING INFLAMMATION - The present invention relates to agents, and methods for identifying compounds, which agents and compounds result in the inhibition of the activation of macrophages. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by activation of macrophages including infections, allograft reactions, inflammation, allergic and autoimmune diseases, metabolic disease, cardiovascular disease, tissue injury, and cancer. | 01-05-2012 |
20120010127 | Compositions Comprising Multiple Bioactive Agents, and Methods of Using the Same - In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent. | 01-12-2012 |
20120015870 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 01-19-2012 |
20120015871 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120015872 | COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS - Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system. | 01-19-2012 |
20120021975 | ANTIBIOTIC PEPTIDES - The invention relates to a peptide or peptide derivative having the general formula: Sub | 01-26-2012 |
20120028883 | COMPLEX AND PRODUCTION PROCESS - A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed. | 02-02-2012 |
20120040887 | COMPOSITION FOR THE TREATMENT OF OSTEOMYELITIS, METHOD FOR PREPARING THE SAME, AND METHOD FOR THE TREATMENT OF OSTEOMYELITIS - The disclosure provides a composition for the treatment of osteomyelitis and a method for preparing the same. The composition includes: 100 parts by weight of water; 0.06-0.1 parts by weight of an antibiotic; and 5-40 parts by weight of a biodegradable thermosensitive polymer, wherein the biodegradable thermosensitive polymer has a structure as following: | 02-16-2012 |
20120071397 | Methods for Hematopoietic Stem Cell Transplantation - The present invention provides methods for treating a subject undergoing hematopoietic stem cell transplantation, methods for increasing a subject's resistance to bacterial or viral infection during and/or following hematopoietic stem cell transplantation, and methods for treating norovirus infection. | 03-22-2012 |
20120077736 | INHIBITOR AGAINST FORMING BIOFILM COMPRISING K-CASEIN MACROPEPTIDE - An inhibitor against the formation of biofilm includes κ-casein macropeptide. The inhibitor prevents or reduces the formation of a biofilm by inhibiting attachment or attachment/invasion followed by biofilm formation on the abiotic or biotic surfaces by | 03-29-2012 |
20120122766 | Novel Polypeptide Having Angiogenesis-Inducing Activity And Antibacterial Activity, And Use Thereof For Medical Purposes - Novel polypeptides which have an excellent angiogenesis-inducing activity and an excellent antibacterial activity and medical uses thereof are disclosed. The amino acid sequences of the novel polypeptides are shown in any one of SEQ ID NOs:1 to 6. These polypeptides have angiogenesis-inducing and antibacterial activities. Such polypeptides are useful for the prevention, amelioration or treatment of skin wounds caused by a cut wound, surgical wound, erosion, burn, decubitus, intractable wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease or arteriosclerosis obliteran, and for the prevention, amelioration or treatment of bacterial infection in such skin wounds, and the like. | 05-17-2012 |
20120129762 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO - The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. | 05-24-2012 |
20120165246 | Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor - The present invention provides a method of specifically detecting the presence of one or more Mycobacteria of the | 06-28-2012 |
20120172287 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide - A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran. | 07-05-2012 |
20120184482 | Novel Ubiquitin-Isopeptide Probes - The invention relates to a ubiquitin-isopeptide probe (hereinafter also referred to as UIPP), a method for its preparation, and its use. The invention also provides a method for isolating a deubiquitinating enzyme and a method for activity-based protein profiling (ABPP). | 07-19-2012 |
20120202734 | ANTIBIOTIC, ITS NUCLEOTIDE SEQUENCE, METHODS OF CONSTRUCTION AND USES THEREOF - The present invention belongs to field of biology and medicine, and especially relates to a novel antibiotic, its nucleotide sequence, methods of construction and uses thereof. A novel antibiotic, wherein the end of any peptide of the allosteric colicin is connected linearly to the end of peptide of the | 08-09-2012 |
20120202735 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 08-09-2012 |
20120238491 | IMMUNOLOGICALLY ACTIVE LIPOPEPTIDES AND METHODS FOR USE THEREOF - The present invention relates to the isolation and structure elucidation of 1-peptidyl-2-arachidonoyl-3-stearoyl glyceride (pDAG) as an active chemical entity in the caprine serum fraction, and the discovery of the innate immune modulating activity of pDAG as an endogenous damage associated molecular pattern | 09-20-2012 |
20120252720 | COMPOSITIONS FOR TREATMENT OF EAR DISORDERS AND METHODS OF USE THEREOF - The present invention relates to compositions and methods useful for the treatment of ear disorders, administered to a treated ear in the form of a foam or a mousse. Administering a medicament in such forms will increase the residence time of the medicament in the ear canal, provide relatively uniform distribution of the composition, and can increase the penetration of the active pharmaceutical ingredient in the affected area, may release active substances slowly, enhance treatment effectiveness, increase compliance and is more convenient to use than currently available ear medications. The administration in the form of a foam or a mousse may preferably be provided as a metered dose, of a volume suitable to fill the ear canal. | 10-04-2012 |
20120264678 | METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES - Disclosed are methods of treating infectious diseases comprising administering to an animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent. | 10-18-2012 |
20120283173 | NOVEL COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTION - The invention relates to a HNK-I mimetic peptide or a polypeptide comprising such HNK-I mimetic peptide for treating or preventing a | 11-08-2012 |
20120283174 | ANTIBIOFILM GLYCOPEPTIDES - The present invention relates to peptides and compositions that have antibiofilm properties. In particular, the peptides and compositions of the invention can be used for the treatment or prevention of various conditions including dental caries, gingivitis, periodontitis, oral mucositis, dry mouth and xerostomia. | 11-08-2012 |
20120289455 | Monocarbams - The invention relates to compounds of formula (I): | 11-15-2012 |
20120295837 | NOVEL ANTIMICROBIAL AGENTS - A novel class of antimicrobial polymeric agents, which include a plurality of amino acid residues, such as positively charged amino acid residues, and at least one hydrophobic residue linking therebetween, such as an omega-amino-fatty acid residue, designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms, a medical device, an imaging probe and a food preservative utilizing same. Further disclosed are conjugates of an amino acid residue and a hydrophobic moiety residue and a process of preparing same. | 11-22-2012 |
20120295838 | Selective poly-substituted glycine antibiotics and related compositions - Antimicrobial peptoid compounds and related compositions as can be used against bacteria effectively and selectively. | 11-22-2012 |
20130012428 | LIQUID ANTIMICROBIAL COMPOSITIONS - The present invention relates to liquid antimicrobial compositions having a high anti-microbial activity. The invention further relates to a method for preparing the liquid antimicrobial compositions as well as their use as a preservative in food products. | 01-10-2013 |
20130029902 | CXC CHEMOKINE RECEPTOR 4 (CXCR4) ANTAGONISTIC POLYPEPTIDE - A peptide having the following amino acid sequence: | 01-31-2013 |
20130059773 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATION AND NEUTROPENIA - The present invention concerns compounds modulating apoptosis of neutrophil cells. In particular, the invention concerns compounds inhibiting an interaction between Proliferating Cell Nuclear Antigen (PCNA) and proteins binding to cytoplasmic PCNA in neutrophil cells, for use in the treatment of a disease involving a neutrophil-dependent inflammatory process. The invention also relates to a method for the identification of a compound for use in the treatment of a neutrophil-dependent inflammatory process. The invention further relates to peptides for use in the treatment of neutropenia. | 03-07-2013 |
20130096051 | LECTINS AND USES THEREOF - The present invention relates to chemical compounds, methods for their discovery, and their therapeutic and re-search use. In particular, the present invention provides antiviral and antimicrobial lectin compounds (BanLec) isolated from bananas. These compounds have low mitogenicity and pro-inflammatory activity whilst maintaining anti-HIV-1 activity. | 04-18-2013 |
20130130969 | ANTIMICROBIAL PEPTIDE, BRANCHED FORMS THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIA INFECTIONS - The instant invention refers to an antibacterial peptide with all aminoacids in D-configuration, possessing strong antimicrobial activity against Gram-negative and Gram-positive bacteria and | 05-23-2013 |
20130150285 | THERAPEUTIC AND COSMETIC USES AND APPLICATIONS OF CALRETICULIN - Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles. | 06-13-2013 |
20130157931 | MITOCHONDRIAL PENETRATING PEPTIDES AS CARRIERS FOR ANTIMICROBIALS - There is described herein compounds comprising a mitochondrial penetrating peptide (MPP) conjugated to an antimicrobial, and their method of use. | 06-20-2013 |
20130203652 | DIFFOCINS AND METHODS OF USE THEREOF - This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill | 08-08-2013 |
20130203653 | BACTERIAL-DERIVED BLIS FOR TREATMENT OF ACNE - This invention relates to a treatment of acne. Specifically, the invention is directed to the use of bacteriocin-like inhibitory substances (BLIS), isolated from | 08-08-2013 |
20130210707 | PEPTIDE HAVING ANTIMICROBIAL OR ANTI-INFLAMMATORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT - The present invention relates to a peptide having antibacterial or anti-inflammatory activity and a pharmaceutical composition containing the same as an active ingredient, and more particularly to a peptide having antibacterial or anti-inflammatory activity against dental bacteria, including periodontal pathogens, and bacteria causing atopic dermatitis, and to a pharmaceutical composition containing the peptide as an active ingredient. The inventive peptide having antibacterial or anti-inflammatory activity can be used for the treatment of both dental infectious diseases, including periodontitis or peri-implantitis, and inflammations, including atopy, psoriasis or arthritis. | 08-15-2013 |
20130231275 | AMINIOTHIAZOLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases particularly bacterial infections. | 09-05-2013 |
20130244928 | ANTIMICROBIAL PEPTIDES AND DERIVED METAPEPTIDES - The peptides and derivative metapeptides based upon natural antimicrobial peptides have potent and broad spectrum activity against pathogens exhibiting multiple antibiotic resistance. Specific peptides can also potentiate the antimicrobial functions of leukocytes, such as neutrophils. In addition, they exhibit lower inherent mammalian cell toxicities than conventional antimicrobial peptides, and overcome problems of toxicity, immunogenicity, and shortness of duration of effectiveness due to biodegradation, retaining activity in plasma and serum. The peptides and derivative metapeptides exhibit rapid microbicidal activities in vitro, can be used to potentiate conventional antimicrobial agents, to potentiate other antimicrobial peptides and are active against many organisms that exhibit resistance to multiple antibiotics currently in existence. | 09-19-2013 |
20130252880 | Dendrimeric Peptides, Pharmaceutical Compositions And Methods Of Using The same - Novel dendrimeric peptide compounds are disclosed that have a formula represented by the following formula I: | 09-26-2013 |
20130267457 | PEPTIDE INHIBITORS OF PROTEIN SYNTHESIS - The present invention discloses compositions of peptide inhibitors of protein synthesis, and methods of identifying peptide inhibitors that are capable of inhibiting protein synthesis through an interaction at a stem-loop H18 in 16S rRNA of a 30S ribosomal subunit. Screening methods for peptides are disclosed, in addition to methods of determining the affinity of a test compound for a ribosomal subunit. | 10-10-2013 |
20130274173 | STABLE HELICAL IONIC POLYPEPTIDES - The invention provides polymers comprising Formula I: | 10-17-2013 |
20130296227 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 11-07-2013 |
20130338058 | USE OF LIPID CONJUGATES IN THE TREATMENT OF CONJUNCTIVITIS - In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis. | 12-19-2013 |
20130345119 | MULTIMERIC ANTIMICROBIAL PEPTIDE COMPLEX WHICH IS DISPLAYED ON CELL SURFACE - The present invention provides an antimicrobial peptide polymer comprising at least one monomer which is digested by pepsin, a multimeric antimicrobial peptide complex comprising the polymer and a cell surface anchoring motif linked to the polymer, an antimicrobial microorganism displaying the multimeric antimicrobial peptide complex, an antimicrobial composition comprising the same, a method of treating an infectious disease caused by bacteria, yeast or fungi by administering the antimicrobial composition, and a method for producing the antimicrobial microorganism. According to the invention, living microorganisms displaying an antimicrobial peptide on the cell surface thereof may be administered in vivo without having to lyse the microbial cell and isolate and purify the antimicrobial peptide, so that the antimicrobial peptide exhibits antimicrobial activity. Thus, the antimicrobial peptide may be produced at significantly reduced costs so that it may have widespread use. | 12-26-2013 |
20140018287 | BRIDGE-HELIX CAP: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - It has been discovered that the Sal target represents a new and promising target for antibacterial drug discovery. The Sal target is distinct from the rifamycin target and from the CBR703 target. This indicates that antibacterial compounds that function through the Sal target should exhibit no, or minimal, cross-resistance with rifamycins and CBR703. This further implies that it should be possible to co-administer antibacterial compounds that function through the Sal target together with a rifamycin, together with CBR703, or together with both a rifamycin and CBR703, in order to achieve additive or synergistic antibacterial effects and in order to suppress or eliminate the emergence of resistance. | 01-16-2014 |
20140024576 | HEPTOSE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS - Compounds having the general formula (I) pharmaceutical compositions containing them for use in inhibiting bacterial heptose biosynthesis and thereby lowering or suppressing bacterial virulence. | 01-23-2014 |
20140038882 | Stable Pexiganan Formulation - The invention provides chemically and physically stable topical formulations of pexiganan, and methods of preparing the same. | 02-06-2014 |
20140066363 | CARBOHYDRATE NANOPARTICLES FOR PROLONGED EFFICACY OF ANTIMICROBIAL PEPTIDE - A nanoparticle includes a carbohydrate carrier and a bacteriocin. A method for prolonging efficacy of a bacteriocin against a food pathogen includes providing the bacteriocin in a delivery system, and inhibiting the food pathogen by the bacteriocin. A duration of efficacy of the bacteriocin against the food pathogen when the bacteriocin is provided in the delivery system exceeds a duration of efficacy of the bacteriocin when the bacteriocin is provided without the delivery system. | 03-06-2014 |
20140094401 | MITRECIN A POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY - The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell. | 04-03-2014 |
20140128312 | Antimicrobial lytic peptides - This invention relates to novel lytic peptides which are effective in treating citrus plant diseases including canker and greening. The invention also relates to antimicrobial compositions comprising lytic peptides and the use of such compositions in methods for treating diseases of citrus plants. | 05-08-2014 |
20140128313 | ANTIMICROBIAL PEPTIDES AND USES THEREFORE - Materials and methods for making and using cationic anti-microbial peptides (CAMPs), and compositions containing such peptides. | 05-08-2014 |
20140148378 | ANTIBACTERIAL PEPTIDES - The present invention relates to antibacterial peptides and analogs thereof, e.g., originating from, derived from, isolated and/or purified from mammalian milk, that reduce, inhibit and/or prevent the growth or proliferation of a bacterial organism. | 05-29-2014 |
20140148379 | Control of Unwanted Bacteria in Fermentation Systems with Bacteriocin - A method of controlling unwanted bacteria in fermentation processes comprising contacting reactants of the process with an effective amount of bacteriocin. Bacteriocin, both indigenous and produced from independent sources, and optionally bacteriocin plus bacteriophages virulent for unwanted bacteria are used to reduce and control unwanted bacteria. | 05-29-2014 |
20140148380 | MOLECULAR ROADBLOCKS FOR RpoN BINDING SITES - The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the −24, −12, or −24/−12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided. | 05-29-2014 |
20140155318 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 06-05-2014 |
20140194344 | FUSION PEPTIDE DESIGNED TO REDUCE PLAQUE BACTERIA AND YEAST IN THE ORAL CAVITY - The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease. | 07-10-2014 |
20140221273 | Anti-Microbial Peptides and Methods of Use Thereof - The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth. | 08-07-2014 |
20140243255 | TREATMENTS FOR MYCOBACTERIUM TUBERCULOSIS - The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1. | 08-28-2014 |
20140256614 | COMPOSITIONS AND METHODS FOR AUGMENTING PERMEABILITY BARRIERS - Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein. | 09-11-2014 |
20140274876 | CARIES RISK TEST FOR PREDICTING AND ASSESSING THE RISK OF DISEASE - Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level. | 09-18-2014 |
20140274877 | HYDROCHLORIDE SALTS OF AN ANTIBIOTIC COMPOUND - The present invention relates to a compound of formula I: | 09-18-2014 |
20140274878 | AMINOTHIAZOLES AND THEIR USES - The present application describes organic compounds of Formula (I) | 09-18-2014 |
20140287988 | MACROGOL 15 HYDROXYSTEARATE FORMULATIONS - Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder. | 09-25-2014 |
20140287989 | Compounds Binding to the Bacterial Beta Ring - The present invention relates to compounds which bind to the hydrophobic pocket of the β clamp, i.e., to the surface of the β ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target. | 09-25-2014 |
20140296132 | Anti-bacterial Polypeptides and Pathogen Specific Synthetic Antibodies - The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants. | 10-02-2014 |
20140303070 | PROCESS FOR THE MANUFACTURE OF AJOENE DERIVATIVES - The present invention relates to the compound (E,Z)-ajoene of formula (1) for use in treatment of bacterial infections. Another aspect of the present invention is a composition comprising (E,Z)-ajoene of formula (1) and at least one antibiotic. Yet another aspect of the invention relates to a method for manufacturing (E,Z) ajoene of formula (1) wherein the conformation of the internal C═C— bond can be either E or Z or a mixture thereof, said method comprising reacting allicin of formula (3) with an acid in the presence of a solvent to provide (E,Z ajoene) of formula (1) as defined above. Yet another aspect of the invention is (E,Z)-ajoene of formula 1 obtainable by the method described above. | 10-09-2014 |
20140309161 | Modified antibiotic peptides having variable systemic release - The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (PEG). The peptide linker contains a recognition sequence for trypsin-like serum proteases. In the apidaecin derivatives, the linker and the PEG are bonded to a side chain. In the serum, the linker is cut by serum proteases and PEG is separated off. The released peptide still contains remnants of the linker, which are still bonded to the amino group in the side chain. Astonishingly, said remaining remnants of the linker impair the activity of the antimicrobial peptide only a little or not at all. | 10-16-2014 |
20140309162 | NOVEL ANTIBACTERIAL AND FUNGICIDAL PEPTIDE IN WHICH LYSINE AND TRYPTOPHAN RESIDUES ARE REPEATED, AND USE THEREOF - The present invention relates to an antibacterial and fungicidal peptide in which a lysine and tryptophan dipeptide is repeated. More specifically, the antibacterial and fungicidal peptide of the present invention, in which lysine and tryptophan dipeptide is repeated four times, shows excellent antibacterial activities with respect to gram-positive bacteria, gram-negative bacteria and antibiotic-resistant strains by affecting the inner membrane of harmful microorganisms, has remarkable fungicidal activities with respect to pathogenic fungi and antibiotic-resistant fungi, and shows little cytotoxicity, and thus can be useful for a pharmaceutical composition, a cosmetic composition, agricultural chemicals, a food preservative, a cosmetic preservative, and a pharmaceutical preservative. | 10-16-2014 |
20150045284 | CRYSTAL STRUCTURE OF A TYPE IB P-TYPE ATPase - The present invention relates to crystals of a type IB P-type ATPase having the space group P1 and methods for purification and growing said crystals. The invention also presents methods for identifying an inhibitor of a type IB P-type ATPase for example by determining binding interactions between an inhibitor and a set of binding interaction sites in said type IB P-type ATPase. | 02-12-2015 |
20150045285 | BIOFILM INHIBITOR - The biofilm inhibitor of the present invention contains a lectin, at least one recognizable sugar chain of which is N-acetylglucosamine (G/LcNAc). | 02-12-2015 |
20150057217 | SHORT DESIGNED PEPTIDES POSSESSING SELECTIVE ACTIONS AGAINST BACTERIA AND CANCER CELLS - The present invention relates to amphiphilic peptides having antibacterial and/or antitumor activity, and to therapeutic and non-therapeutic compositions comprising these peptides. The peptides are of structural formula I or II shown below | 02-26-2015 |
20150072920 | ANTIMICROBIAL COMPOSITIONS AND USES THEREOF - The present invention relates to an antimicrobial composition having activity against Gram-positive and Gram-negative bacteria. The composition is a) a composition comprising at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; b) a composition comprising at least two bacteriocin selected from the group consisting of pediocin, Nisin and reuterin; c) a composition comprising pediocin and at least two organic acids selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid; or d) a composition comprising reuterin and at least one organic acid selected from the group consisting of lactic acid, acetic acid, benzoic acid and citric acid. The present invention also relates to the use of said compositions for sanitizing and/or disinfecting surfaces and method thereof. | 03-12-2015 |
20150072921 | METHOD FOR THE APPLICATION OF A SUBSTANCE TO ELIMINATE AN INFECTIOUS AGENT LIVING WITHIN AN INSECT VECTOR AS A MEANS OF CONTROL OF THE SPREAD OR ELIMINATION OF DISEASE - A method of reducing the spread of disease by inhibiting the growth of or eliminating harmful bacteria which are the cause of the disease in an organism or damage to organic material. The method inhibits bacterial growth in the organism without harming the organism or other organisms in the environment. The method includes formulating an antimicrobial agent that is taken up to the vector organism known to spread disease due to the presence of harmful microbes such as bacteria living in the organism. The antimicrobial agent eradicates and/or inhibits the future growth of the bacteria in the organism, thereby leaving the organism free of the infecting bacteria while not being a poison to the organism. | 03-12-2015 |
20150087579 | ANTIMICROBIAL PEPTIDES - A novel antimicrobial peptide includes at least eight successive amino acids, the peptide exhibiting a sequence having the following formula: Ter | 03-26-2015 |
20150087580 | ANTIMICROBIAL CATIONIC PEPTIDES AND FORMULATIONS THEREOF - Compositions and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device. | 03-26-2015 |
20150087581 | Immunosuppression Modulating Compounds - The present invention provides immunosuppression compounds to inhibit the programmed cell death 1 (PD1) signalling pathway. The present invention further provides peptide based compositions for treatment of cancer or treatment of infections via immunopotentiation caused by inhibition of immunosuppressive signaling induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient. Further, the invention provides an application of the compositions containing the peptide moieties for preventive and/or therapeutic agents for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of peptide moieties as a testing or diagnostic agent or a research agent for such a disease. | 03-26-2015 |
20150126433 | GROWTH FACTORS FOR THE TREATMENT OF MYCOBACTERIAL INFECTION - Described herein are novel methods and kits for treating mycobacterium infections with KGF. The methods include administering an amount of KGF effective to treat the mycobacterium infection. The mycobacterium may be | 05-07-2015 |
20150126434 | ANTIMICROBIAL PEPTIDE AND USE THEREOF - A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier. | 05-07-2015 |
20150133365 | Polypeptide Having Antibacterial Activity and Angiogenesis-Inducing Activity and Wound-Healing Drug Containing Said Polypeptide - A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran. | 05-14-2015 |
20150313836 | Dry Pharmaceutical Compositions for Topical Delivery of Oral Medications, Nasal Delivery and to Treat Ear Disorders - In one aspect, a dry formulation for the effective administration of multiple medications simultaneously for one or more ailments may be provided. The dry formulations include one or more of the following actives in combination with pharmaceutically acceptable excipients or additives: a) at least one antibiotic; b) at least one anti-inflammatory steroid; and c) at least one antifungal agent. | 11-05-2015 |
20150315241 | Antibiotic Peptides - This invention concerns novel antibiotic peptide and peptide derivates, especially for use in medicine. Further, the invention relates to compositions and methods for killing microbes, like bacteria or fungus, and methods to treat microbial infections. The invention further relates to a method for drug screening analysis. The peptides and peptide derivates have the general formula Sub | 11-05-2015 |
20150335030 | LIQUID NISIN COMPOSITIONS - The present invention relates to liquid nisin compositions having a high anti-microbial activity. The invention further relates to a method for preparing the liquid nisin compositions as well as their use as a preservative in food products. | 11-26-2015 |
20150336957 | NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS - Compounds of Formula (I), their preparation and use in preventing or treating bacterial infections are disclosed. | 11-26-2015 |
20150374673 | Combination Therapy for the Treatment of Nosocomial Pneumonia - The present invention relates to a method of treatment of nosocomial pneumonia using a combination of ceftazidime (a third generation cephalosporin) and avibactam (a novel β-lactamase inhibitor), optionally with one or more additional therapeutic agents. | 12-31-2015 |
20150374786 | COMPOSITIONS AND METHODS TO INACTIVATE AND/OR REDUCE PRODUCTION OF MICROBIAL TOXINS - The present invention is related to compositions and methods to treat, ameliorate and/or prevent morbidity and/or mortality from microbial infections. In particular, bacterial infections that are associated with the production and release of bacterial toxins. For example, many Clostridia bacteria, such as | 12-31-2015 |
20150376685 | Method for Bacterial Species Identification and Strain Typing - The present disclosure describes a method for identifying a strain or species of bacteria using a single locus sequence typing technique. The single locus useful in the method is the promoter region of the 16S rRNA operon. The method is useful to identify infectious bacteria in a subject, to identifying contaminants in a food source, as well as strain typing and genetic fingerprinting of bacterial families. | 12-31-2015 |
20160031832 | QUINAZOLINONE ANTIBIOTICS - A new class of antibiotics effective against methicillin-resistant | 02-04-2016 |
20160058843 | METHODS AND SYSTEM FOR INTERFERING WITH VIABILITY OF BACTERIA AND RELATED COMPOUNDS AND COMPOSITIONS - Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions. | 03-03-2016 |
20160074480 | INNOVATIVE METHODS OF TREATMENTING TUBERCULOSIS - A Safe and effective treatment methods to cure and curtail tuberculosis affliction described using high dose Vitamin C, and other known anti- | 03-17-2016 |
20160075749 | ANTIMICROBIAL PEPTIDE - The disclosure relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection. | 03-17-2016 |
20160081916 | Topical Composition and Carrier for Administration of Pharmaceutically or Cosmetically Active Ingredients - The present invention provides topical pharmaceutical or cosmetic compositions comprising a pharmaceutical or cosmetic carrier comprising at least 3% by weight of phospholipid; at least 20% by weight of C | 03-24-2016 |
20160095316 | COMPOSITIONS AND METHODS FOR THE REMOVAL OF BIOFILMS - Methods of breaking down a biofilm or inhibiting, preventing or treating a microbial infection that produces a biofilm are disclosed, which involves administration of a polypeptide that has one or more HMG-box domains to a subject suffering from the infection or having the biofilm. By competing with microbial proteins that bind to DNA scaffold in the biofilm, these polypeptides destabilize the biofilm leading to destruction and removal of the biofilm by the immune system. | 04-07-2016 |
20160115196 | SELF-ASSEMBLED MICRO-AND NANOSTRUCTURES - The present invention discloses self-assembled bioadhesive anti-microbial, anti-fouling and/or anti-oxidant micro- and nano-structures comprising a plurality of amino acids or peptides, wherein each amino acid is an aromatic amino acid comprising a catecholic moiety, and/or each peptide comprises at least one aromatic amino acid comprising a catecholic moiety. Further disclosed are methods and kits for preparing these micro- and nano-structures. Further disclosed are uses of these micro- and nano-structures in pharmaceutical, cosmetic and medical devices applications. | 04-28-2016 |
20160120936 | METHODS OF PREVENTING SURGICAL SITE INFECTIONS - Methods for preventing a tissue infection associated with the site of a tissue disruption, such as a surgical incision. The methods include contacting tissue at the site with a composition comprising ε-polylysine in a physiologically-acceptable carrier, such as an isotonic solution, powder or hemostatic material containing ε-polylysine. Also provided are kits for preparing antibacterial ε-polylysine compositions. | 05-05-2016 |
20160120946 | COMPOSITIONS COMPRISING GC-MACROPHAGE ACTIVATING FACTOR AND USES THEREOF - A pharmaceutical composition that includes stable Gc macrophage activating factor (GcMAF) or a biologically active variant or fragment thereof and at least one pharmaceutically acceptable excipient selected from the group consisting of a surfactant and a synthetic water-soluble polymer having surface activity. These compositions are storage stable and are used for treating a disease or disorder associated with macrophage activation. | 05-05-2016 |
20160130309 | MONOCINS AND METHODS OF USE - The disclosure relates to the identification, cloning, and expression of a genetic locus within a | 05-12-2016 |
20160145304 | CYSTOBACTAMIDES - The present invention provides cystobactamides of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections: | 05-26-2016 |
20160158315 | RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS - The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of nasal rhinitis, nasal sinusitis, chronic rhinosinusitis, and nasal polyposis. More particularly, the invention provides methods, including broadly the critical dosage ranges of rhCC10 and intranasal route of administration, which may be administered to safely and effectively treat the aforementioned conditions. The invention further provides a composition useful in administering rhCC10 to humans. | 06-09-2016 |
20160184220 | Method for the Prevention and Treatment of Acne - A system for treating and preventing multiple forms of acne includes applying a solution to the skin to assist maintaining the skin's natural acidic mantle of 4.0 to 6.5, preserve moisture transport properties, and maintain specialized lipid content, allowing the skin to function normally, and assisting the skin to heal wounds caused by acne and associated bacterial infections. The method steps include one or more of the following: applying the formulation with surfactants incorporated therein to the skin as a cleanser, rinsing with water; applying the solution, with or without surfactants, and allowing the solution to air dry; repeating the applications and allowing them to air dry throughout the day; and repeating the cleansing and rinsing steps and applying the solution and allowing to air dry before retiring. One or more of the method steps may be repeated on a continual basis, typically daily, for an extended period of time. | 06-30-2016 |
20160250283 | COMPOSITIONS AND METHODS FOR PROPHYLAXIS AND THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION | 09-01-2016 |
20160376318 | POLYPEPTIDE, DNA MOLECULE ENCODING THE POLYPEPTIDE, VECTOR, PREPARATION METHOD AND USE - A polypeptide, a DNA molecule encoding the polypeptide, a vector, a preparation method and a use therefor are disclosed. The polypeptide comprises an amino acid sequence represented by formula (I) or formula (II): formula (I) comprises an amino acid sequence represented by SEQ ID NO: 1; formula (II) comprises an amino acid sequence obtained by subjecting the amino acid sequence represented by SEQ ID NO: 1 to modification, substituted, and deletion or addition of one or more amino acids. The polypeptide may be used in the preparation of drugs that treat or prevent diseases related to infections caused by bacteria, and can also be used in the preparation of drugs that promote tissue repair and wound healing. | 12-29-2016 |
20190144510 | MODIFIED ANTIMICROBIAL PEPTIDE DERIVED FROM AN ARGININE-RICH DOMAIN | 05-16-2019 |
20100331261 | USE OF ALPHA-1-ANTITRYPSIN FOR THE PREPARATION OF DRUGS FOR THE TREATMENT OF CHRONIC FATIGUE SYNDROME - The present invention relates to the use of alpha-1-antitrypsin for the preparation of effective drugs for the treatment of chronic fatigue syndrome. In addition, the present invention relates to the use of plasma or other therapeutic forms with an alpha-1-antitrypsin content sufficient to obtain a dose of 6 mg or more of alpha-1-antitrypsin per kg of body weight at a frequency of between 1 and 31 days. | 12-30-2010 |
20110251136 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 10-13-2011 |
20130252906 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH ALPHA-1-ANTITRYPSIN - Pharmacological chaperone compounds and methods for the treatment of an individual having, or at risk of having, a disease condition associated with alpha-1-antitrypsin by using said compounds are disclosed. In particular, such methods are useful for the treatment or prevention of lung disorders associated with alpha-1-antitrypsin deficiency as well as liver disorders associated with an excess of alpha-1-antitrypsin. Suitable pharmacological chaperones include peptides and low-molecular weight compounds. Also provided is an assay for determining whether a test compound modulates alpha-1-antitrypsin activity. | 09-26-2013 |
20130310325 | ADMINISTRATION OF SERINE PROTEASE INHIBITORS TO THE STOMACH - The inventors have unexpectedly discovered that shock and/or potential multi-organ failure due to shock can be effectively treated by administration of liquid high-dose protease inhibitor formulations to a location upstream of where pancreatic proteases are introduced into the gastrointestinal tract. Most preferably, administration is directly to the stomach, for example, via nasogastric tube under a protocol effective to treat shock by such administration without the need of providing significant quantities of the protease inhibitor to the jejunum and/or ileum. | 11-21-2013 |
20140073588 | GLUE COMPOSITION FOR LUNG VOLUME REDUCTION - The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema. | 03-13-2014 |
20140213531 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH PROTEASE INHIBITORY ACTIVITIY - Template-fixed β-hairpin peptidomimetics of the general formulae | 07-31-2014 |
20140371160 | NOVEL ALPHA-1 ANTITRYPSIN VARIANT, PREPARATION METHOD THEREOF AND USE THEREOF - A novel alpha-1 antitrypsin variant, a method of preparing the same, and use thereof are provided. The alpha-1 antitrypsin variant has excellent stability in the body and maintains an inhibitory effect on elastase activities because the blood half-life (t | 12-18-2014 |
20150011479 | Alpha1 proteinase inhibitor peptides methods and use - The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α | 01-08-2015 |
20150025019 | Method for Dosage Adjustment of Drugs that Prevent Elastic Fiber Breakdown - Elastic fiber damage is responsible for the distention and rupture of alveolar walls in chronic obstructive pulmonary disease (COPD). The current invention comprises a method of adjusting the a dosage of a drug that prevents such elastic fiber damage by employing a feedback loop consisting of measuring the levels of the unique elastic fiber breakdown products, desmosine and isodesmosine in body fluids, preferably sputum. The recent discovery that sputum levels of desmosine and isodesmosine are responsive to treatment with aerosolized hyaluronan in COPD patients makes dosage adjustment both feasible and desirable. This process of dosage adjustment may be applicable to any drug that prevents lung elastic fiber damage, such as alpha-1-antitrypsin, other anti-elastase agents, and antioxidants. It is anticipated that such dosage adjustment will become the “standard of care” in the treatment of COPD patients. | 01-22-2015 |
20150320846 | METHODS OF TREATMENT USING ALPHA-1-ANTITRYPSIN COMPOSITIONS - A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described. | 11-12-2015 |
20160011207 | DIAGNOSIS AND THERAPY OF CHRONIC INFLAMMATION-INDUCED DISORDERS | 01-14-2016 |
20160103138 | METHODS FOR ANALYZING ELASTIC FIBER INJURY MARKERS AND DIAGNOSIS OF DISEASES ASSOCIATED WITH ELASTIC FIBER INJURY - The present invention provides, inter alia, methods for measuring the amount of a marker of elastic fiber injury in a sample. The methods include contacting a sample with a compound of formula (1) and carrying out mass spectrometry on the sample containing the compound of formula (1). Also provided are methods of diagnosing whether a subject has a disease characterized by elastic fiber injury, a method for improving the accuracy and precision of mass spectroscopy analysis of a marker of elastic fiber injury, and kits for determining, by mass spectrometry, the amount of a marker of elastic fiber injury in a sample from a subject. Further provided are methods for preventing the progression of the effects associated with alpha-1 antitrypsin deficiency (AATD) in a subject with normal lung function. | 04-14-2016 |